MARKET

ANPCY

ANPCY

Angle Plc
OTCQX
2.040
NaN%
Closed 09:30 05/02 EDT
OPEN
--
PREV CLOSE
2.040
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
32.75
52 WEEK LOW
1.200
MARKET CAP
47.97M
P/E (TTM)
-1.8676
1D
5D
1M
3M
1Y
5Y
ANGLE Inks Supplier Agreement with AstraZeneca To Develop A Parsortix-Based Androgen Receptor Detection Assay For Use In Prostate Cancer Studies
Angle will develop a CTC-based AR assay. The company has signed a deal worth £550,000 to develop a prostate cancer test. Assay development will take place in ANGLE's UK laboratories. The project is expected to be completed in Q1 2025.
Benzinga · 5h ago
Weekly Report: what happened at ANPCY last week (0422-0426)?
Weekly Report · 4d ago
Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca
Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca. Angle will develop a novel methodology for CTC micronuclei detection. The 6-month development phase is worth an initial £150,000 to the UK-based company. Angle to tailor the existing DNA damage response assay for use in pharmaceutical R&D.
Seeking Alpha · 04/24 07:16
Weekly Report: what happened at ANPCY last week (0415-0419)?
Weekly Report · 04/22 12:14
Weekly Report: what happened at ANPCY last week (0408-0412)?
Weekly Report · 04/15 12:04
Weekly Report: what happened at ANPCY last week (0401-0405)?
Weekly Report · 04/08 12:10
Weekly Report: what happened at ANPCY last week (0325-0329)?
Weekly Report · 04/01 12:07
Weekly Report: what happened at ANPCY last week (0318-0322)?
Weekly Report · 03/25 12:10
More
About ANPCY
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.

Webull offers Angle PLC (ADR) stock information, including OTCQX: ANPCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANPCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANPCY stock methods without spending real money on the virtual paper trading platform.